A remarkable specific (125)I-Tyr-Ala-hexarelin binding was observed in the human cardiovascular system where the highest binding levels were detected in ventricles, followed by atria, aorta, coronaries, carotid, endocardium, and vena cava. In other experiments on H9c2, cardiomyocyte-specific GHRP binding was found along with a potent antiapoptotic activity.3 The primarily investigated receptor was the growth hormone secretagogue receptor type 1a (GHS-R1a), which was detected in isolated human cardiomyocytes, myocardium, and aorta samples.17 It has been recently shown that GHS-R1a is a sort of “promiscuous receptor” involved in many systems and behavioral patterns such as reward, feeding, and memory, which makes it an attractive pharmacological target.18 Years later, the synthetic GHRP hexarelin was acknowledged as a ligand of another protein identified as CD36, a scavenger receptor that is expressed in various tissues, including monocytes/macrophages and the endothelial microvasculature. Activation of CD36 in perfused hearts by hexarelin was shown to increase coronary perfusion pressure in a dose-dependent manner. Contrariwise, this effect was lacking in hearts from CD36-null mice and hearts from spontaneous hypertensive rats genetically deficient in CD36.19,20 Thus, it is currently accepted that two cardiac receptor subtypes mediate the pharmacological actions of GHRP-6, GHRP-2, and hexarelin.21,22


In March 1972, the Drugs and Poisons Schedule Subcommittee (DPSSC) decided to include vitamin D in Schedule 4 when the recommended daily dosage on the label exceeds 10 micrograms. This recommendation was based on a recommendation by the Nutrition Committee of the National Health & Medical Research Council that the attention of pharmaceutical firms be drawn to the dangers of vitamin A overdose.
Because some GHRP’s are equally effective as others in increasing GH but differ in effect on hunger or ACTH stimulation, it seems likely that there may be differences in ghrelin receptors between different tissues, or differences in function (for example with cofactors.) This is the most likely explanation for GHRP-6 being effective in stimulating hunger and helping heal tendinitis, while GHRP-2 stimulates hunger less and may have less value for healing.
Figure 6: Microscopic aspect of the rabbits’ ears wounds. (a) Representative image of “nipple” in which, above the cartilage and the perichondrium, there is a prominent accumulation of extracellular matrix. (b) Representative image of the effect induced by the GHRP-6 intervention. Note the reduction of extracellular matrix accumulation within the injured area. The “flattening” aspect is indicated by the solid line arrow. The dotted arrows indicate that the elevation within the center of the scar is similar to the adjacent intact skin. Images suggest that GHRP-6 reduced the local hypercellularity associated with the cartilage cells response. H/E 10x magnification.
The most important initial historical time points in the development of the enlarging ghrelin system were 1973, 1976, 1982, 1984, 1990, 1996, 1998, and 1999 during which the following sequentially occurred: isolation of somatostatin; discovery of unnatural growth-hormone-releasing peptides (GHRPs); isolation of growth-hormone-releasing hormone (GHRH); hypothesis of a new natural GHRP different from GHRH; GHRP+GHRH synergism in humans; discovery of the growth hormone secretagogue GHS/GHRP receptor; cloning of the receptor; isolation; and identification of the new natural endogenous GHRP ghrelin.1

CJC 1295 is a fast working growth hormone releasing hormones devised to reduce the effects of ageing. It works by stimulating the body’s natural growth hormone production and the release of IGF-1. The advantages of the CJC peptide is it helps increases bone density and collagen, as well as boosting the immune system. It will also produce new muscle cells which will be leaner and increases weight loss. The CJC 1295 results are part of years of scientific studies. It primarily increases the production of proteins, which leads to stable bodily functions related to the glands in the body or the endocrine system.
Our first human GHRP-6 studies in normal young men were performed in collaboration with Michael Thorner (Bowers et al., 1990). These studies (Fig. 1.7, left panel) revealed that iv bolus GHRP-6 released GH and, when given together with GHRH, released GH synergistically. One of the most characteristic and consistent in vivo actions of GHRPs in various animals as well as humans of both sexes and all ages is the synergistic release of GH when GHRP is administered concomitantly with GHRH by iv bolus. Subsequently, this was also found for continuous 24/7 subcutaneous (sc) infusion. Also recorded in Fig. 1.7, right panel, is the comparative GH-releasing effects of iv bolus GHRP-6, -1, -2, and GHRH in normal young men. The potency of the three GHRPs we developed over several years was increasingly effective in releasing GH, and each released more GH than GHRH in normal young men. In addition, this was also found to occur in normal young women (Bowers, 1996).
You’ve already learned that sufficient protein intake (above 0.5g/lb of body weight) can assist with adequate IGF-1 and growth hormone production. Whey protein provides your body with a complete profile of necessary amino acids, including leucine. Leucine is an amino acid that promotes greater muscle protein synthesis and assists the body while gaining lean muscle mass and losing fat tissue simultaneously.
Well, personally I used 150mcg injected directly into the joints or areas that I've had any niggling injuries, the localized effect it has on collagen growth is nothing short of astounding. After using GHRP-6, I have personally recovered from a full pectoral tendon tear, where the tendon ripped right of the humerus bone; in fact, it's now in better shape than it was prior to the injury. Interestingly, 5g of the GHRP-6 will last ages when used properly; even at this dose fat loss is noticeable and the anabolic effects of increased muscle size and strength can be seen.

While GHRP-6 is capable of inducing large increases in GH production when used alone, a given dose will show markedly more effect what a GHRH (growth hormone releasing hormone) peptide is taken at the same time. Alternately, when combining a GHRH with GHRP-6, only about half or a third as much GHRP-6 is needed to obtain the same increase in GH production.


If you’re looking to increase your muscle growth and improve strength, whether for competitive bodybuilding or to achieve a personal physique goal, our Australian muscle building peptide supplements can help. Our dedicated research and product development team have consistently produced new products that perform better than other supplement brands, so you know you’ll be getting the best peptide supplements available. If you’re new to peptide supplements and have questions, read our FAQ’s, or alternatively email us at info@musclepeptidesaustralia.com.au and our clinic doctor can help you with your questions.
The scheduling of paracetamol and caffeine when combined in a compound analgesic as the only two active ingredients was amended from Schedule 4 to Schedule 2 by the NDPSC at its 50th Meeting in June 2007. Evidence reviewed by the Committee at that time conclusively demonstrated that the key ingredient in terms of analgesic overuse and nephropathy was phenacetin and not caffeine. It was agreed that the indications for use, safety profile and potential for misuse met the criteria for a Schedule 2 medicine.

There is the potential for the side effects associated with use of growth hormone when growth hormone secretagogues are used, particularly if the use is not under medical supervision. There are limited data on the safety of intravenous and subcutaneous use of AOD-9604 and on the long-term oral use of AOD-9604 in doses in excess of those used in clinical trials.
High testosterone at this stage will accelerate the process. The SARMs are not testosterone, and don’t get metabolised into DHT (nor estradiol). The SARMs selectively bind to the androgen receptor in muscle and bone and amplify the effect of testosterone and DHT there, while not amplifying the effect on other tissue ie skin, prostate. However, through inheritance, if you have hair androgen receptors that are similar to muscle/bone androgen receptors, then SARMs can amplify the androgen message in the hair follicles, and if the inherited androgen sensitivity is activated, it could lead to accelerated male pattern baldness. This is a very rare variation, and while possible, is uncommon. There are no tests available to determine SARMs effect on your hair follicles, nor to determine when your genetic androgen sensitivity in hair follicles will activate.
Myocardial ischemia/reperfusion damage entails multiple molecular and biochemical mechanisms that each alone is sufficiently injurious to disturb an organ whose mechanical performance is dependent upon the stability of ionic/electrical pumps. Oxidative stress, intracellular calcium overload, pH changes, mitochondrial dysfunction, inflammation, and excessive neurohormones are part of an interactive and self-perpetuating continuum of the myocardial injury cascade (Figure 1). The evidences obtained along the years of experimental screening of the synthetic GHRP suggest that each single member of this family of peptides is able to simultaneously counteract different injurious operators in the myocardial ischemic event.

The peptide therapy protocols (Amino Acid Analogs) prescribed by TeleWellnessMD providers are also known as secretagogues (pronounced se-creta-gog), a substance that promotes secretion. These amino acid chains communicate with the body to produce or release growth hormone. Hence a secretagogue causes the body’s own natural processes to produce growth hormone. Secretagogues do not act as growth hormones but rather stimulate the pituitary gland to secrete your stored growth hormone. The subcutaneous injection route of growth hormone stimulation is a preferred route to help slow down age and environmental reductions in growth hormone levels.


Steve Coggan, Chatswood, Sydney, “I am 48 and been weightlifting for 20 years. I have used CJC 1295 and Ipamorelin on their own and together, and have to say that when combining them they work better and faster. I have been using them for the past year, with 2 rest times. The combination of CJC 1295 Ipamorelin, is proving fantastic all round. Not only am I increasing muscle, my weight is down, but my skin is looking great. Some of the bags under my eyes have more or less gone. My missus thinks I look 10 years younger! Also, it has helped in the recovery of an injury to my knee after a fall. I have to say it isn’t cheap, but the results are worth it. CJC 1295 Ipamorelin side effects were few, just some headaches at first. You need to use it with a good diet and fitness regime for best results. I will definitely be continuing with it!”
In extracardiac models of striated muscles atrophy, GHRP-2 exerted a potent myoprotective effect, presumably via the direct agonistic stimulation of the GHS-R1a since no elevation of IGF-1 transcript was observed.49 Thus, it is likely that GHRP cardioprotective effects in scenarios of DCM may be somehow mediated by a trophic or anabolic mechanism. Based on the benefits of GHRP-6 on muscle functions, a newly synthesized GHRP-6-biotin conjugate tested on cultured myoblasts showed that it induced the expression of myogenic proteins and IGF-1 levels similar to the concentrations of energy metabolites and the corresponding enzymes. Practical applications of the GHRP-6-biotin conjugate could include amelioration of sarcopenia and/or cardiac cachexia.50
Basic molecular pathophysiological cascade of acute myocardial infarction. Hypoxia triggers an acute failure in mitochondrial respiratory function when the diffusible oxygen stores become exhausted. Adenosine triphosphate reserves are rapidly depleted, and there is a respiratory shift toward an anaerobic profile. Lactate, H+ ions, CO2, and potassium accumulate may lead to arrhythmias, microendothelial damage, myocardiocytes stunning, and cell death. Adenosine triphosphate (ATP) depletion is irrevocably ligated to the inability of maintaining the normal negative resting membrane potential, to an alteration of calcium homeostasis (intracellular Ca2+ ([Ca2+]i) overload), which may eventually lead to different patterns of abnormal cardiac contraction. Mitochondrial functionality becomes abnormal, establishing the so-called “open pore” (mitochondrial permeability transition pore [mPTP]), leading to local cell death. In this scenario, mitochondria turn into an active ROS manufacturing plant that increases and perpetuates mitochondrial damages and dysfunction. The failure of myocardial contractility (contractility depression) is a precocious and multifactorial consequence of ischemia, which may eventually lead to reduced cardiac output and heart failure. This situation may translate into a self-perpetuated vicious circle, thus amplifying the ischemic episode and the myocardial wall stress. The local inflammatory reaction is a useful but critical operator within the myocardial ischemia/reperfusion damage process. Hypoxia itself activates the HIF-α/MIF axis and the consequent downstream inflammatory cascade. The locally secreted pro-inflammatory cytokines are involved in a self-perpetuating process in the ROS chain reaction, inflammation, and cellular damage.
Mostly, these peptides are sold as lyophilized powder in 2mg containers. Bacteriostatic water should be mixed with the powder in order to reconstitute it. To make the dosage of 100mcg per injection, 2ml bacteriostatic water should be mixed into 2mg of lyophilized powder. This reconstituted mixture should be then injected inside the muscles or under the skin. The mixture should be kept under refrigeration at all times otherwise it will degenerate and will not be effective anymore.
200 to 300 mcg is typically the daily dosage which is recommended for the typical Ipamorelin user. It can be taken anytime during the day but is advisable to be used in the morning, as it will help you achieve the best results in such cases. Regardless of when you start your dosage, it is important to ensure you are taking it at the same time each day. And, for new users, it is best to stick to a one-a-day cycle.
These peptides are inhibitors of a protein called myostatin. Myostatin is secreted by muscle cells and acts to essentially block the development of new muscle fibers and, thus, the development of lean muscle mass. In fact, individuals who have mutations in the gene coding for this protein have significantly more muscle mass and enhanced strength. The administration of follastatin peptides can generate enhanced muscle mass and strength, and has been found especially useful in patients suffering from muscle-wasting diseases or who have difficulty gaining muscle.
"a number of weeks in on a S4 research using 5 day on 2day off . Results o far include muscle hardening very noticeable on resting biceps. Strength has increased by 20% with it seems like no end to sets with recovery and endurance unreal. Just when you thought you was done , rest and here we go again. Not a great deal of muscle soreness days later which makes me increase my weights next session. There was a few sides with a elite sensitivity to light to dark and hunger was weird. Not needing to eat but when eating it was awesome. Loved what I eating even more as tho I had been very hungry. Customer service and delivery from you guys was second to none. Ordered on a Sunday received on Tuesday morning. Well packed. Love the ease of use on your web site. Great quality products and service. I can't wait to purchase more from you guys." Arnie
The purpose for which peptides are used determines their legality. For research purposes, it is perfectly all right for you get these compounds if you need to. But then, the discussion here is not about medical research but bodybuilding. It is less likely you are interested in them for the former purpose. Do note that it is illegal to buy and use peptides for purposes other than research.
by Bill Roberts – GHRP-6 is an injectable peptide in the category of growth hormone releasing peptides, or GHRP’s. The most common use of these peptides is to increase GH production. Other peptides in this category include GHRP-2, hexarelin, and ipamorelin. With regard to increasing GH, all of these work similarly, and there is no need or advantage to combining them. Instead, the one most suited for the particular case is chosen.
Results in Fig. 1.8 of normal young men (left panel) and women (right panel) demonstrate that iv bolus combined GHRP-2 and GHRH at the respective doses of 1 μg/kg GHRH and a subthreshold GH-releasing dose of 0.03 μg/kg GHRP-2 released GH synergistically (Bowers, 1998). From these studies, GHRP is envisioned to act on the hypothalamus to release an unknown factor (U factor) rather than endogenous GHRH which subsequently acts concomitantly with GHRH on the pituitary somatotroph to release GH synergistically. In this study, the important specific finding is that GHRP-2 augments GHRH release even when GHRH is present in excess amounts, and the concomitant GHRP-2 dose of 0.03 μg/kg is a subthreshold GH-releasing amount. Thus, GHRP + GHRH is not releasing GH in this study by augmenting endogenous GHRH release and, furthermore, GHRP+GHRH release in vitro is additive and not synergistic. In addition, from other high-dosage GHRP-2 data, that is, 10 μg/kg sc (not shown), we have postulated that at high doses GHRPs do act on the hypothalamus to release endogenous GHRH because high-dose GHRP-2 (10 μg/kg sc) releases the same large amount of GH released by combined GHRH + GHRP-2 at 1 + 1 μg/kg iv (Bowers, 1998a,b).
GHRP’s have been used whilst steroid cycling, but due to their nature and comparative weakness to steroids and the like, I find the best use of these compounds is during and after post cycle therapy in an attempt to keep as much of the steroid-induced gains as possible as well as helping the users mind-set as they still feel like they are ‘on’ something…sad but true. GHRP’s are also cycled in an alternate fashion with GH (and IGF), so as to keep the body’s natural GH production systems from de-sensitizing and shutting down completely…much in the same way that steroid users alternate HCG with steroids; to keep the natural testosterone system functioning optimally.

Determining how efficient and the actions of the growth hormone is dependent on the physical condition of the experimental unit. For example, in humans, GH secretion decreases with obesity. On the other hand, GHRP-6, similar to Hexarelin, showed in one case increased (almost twice that of GHRP) GH responses when administered in obese patients (Cordido et al. 1993). Though obesity has shown affecting the efficiency of the hormone, it was also suggested that GHRP-6’s effects were found to be sex- and age-independent without being affected by the noadregenic pathways using the a2 adrenergic receptors (Penalva et al. 2008).
It is extremely important to create awareness among the masses, that procuring illegal drugs off the black market or the internet is an offence under the federal law, being guilty of which can lead to a long jail sentence. Secondly, people should be made aware of the fact that drugs procured through illegal means may be fake or adulterated with other steroids or addictive agents.

When you are just getting started with Ipamorelin, it is advised to use only one supplement daily at the same time each day. It is also advised to begin on the lower end, typically an eight-week cycle, and at a maximum twelve-week cycle. Doing this not only guarantees the desired results when using Ipamorelin, it is also going to ensure you get the most out of the supplement. When using this dosage cycle you will:
The wounds were monitored and followed from day 14 until day 30 after wounding so as to detect the nodular firm consistency that precedes the clinical exuberance. The animals remained in observation for another 20 days after GHRP-6 administration had been completed. The incidence of firm, protruded nodules with nipple-like appearance arising in resurfaced wounds was registered weekly until day 50. After euthanasia (anesthesia overdose), the samples were collected in block, longitudinally bisected along the largest point of nodular growth. One hemisection was nitrogen frozen for additional studies and the other one was fixed in 10% neutral buffered formaldehyde and processed for histology. Five-micrometer sections were stained with H/E staining. Scar overgrowth was measured using the previously described scar elevation index (SEI) based on the cross-sectional scar area to the area of tissue excised to induce the wound [21]. Blinded researchers measured the sections using the ImageJ software package, version 1.46r.
The letters stand for ‘Growth Hormone Releasing Peptide’, and the compound is a peptide in the growth factor family, known as a HEXAPEPTIDE and GH SECRATAGOGUE. It has a strong effect on the release of endogenous (naturally produced) human growth hormone, in a dose related manner. It has been used in school medicine for the treatment of growth hormone deficiency in children and young adults, which drives home just how powerful this compound is at influencing the body to release its own natural GH. It works by signalling the pituitary gland to secrete GH itself, but also by the suppression of SOMATOSTATIN too (an antagonist of growth hormone releasing hormone – GHRH).
Depending on the intended use, and your desired results, the dosage levels are going to vary from person to person as well. So, keep this in mind when trying to determine how great the results are actually going to be when you are using Ipamorelin. So, what exactly can you expect when using this supplement? Some things you will see, for every user is:
Another side effect of the CJC-1295 is acromegaly, since it helps in increasing the levels of the growth hormone. Acromegaly is a condition where extra growth hormone is released even after the internal organs and the skeleton have finished growing. This causes thickening of the skin, deepening of voice, enlargement of jaws, and slurring of speech. Another effect of acromegaly is the swelling of the soft tissue in the internal organs. This could result in the weakening of the muscles of the internal organs, like the heart. This was tested during the phase 2 testing of CJC-1295.
Conclusions: Subcutaneous administration of CJC 1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 ug/ kg. There was evidence of a cumulative effect after multiple doses. These data support the potential utility of CJC 1295 as a therapeutic agent.
The delegates have decided to accept the advice of the expert advisory committees that the current scheduling of preparations in Schedules 5 and 6 remains appropriate. The delegates noted the decision to retain listing of teeth whitening preparations containing up to 6 per cent hydrogen peroxide or 18 per cent carbamide peroxide in Schedule 5, or exempt when below 3 per cent and 9 per cent respectively, is to some extent also consistent with the evaluation of such products by the European Commission Scientific Committee on Cosmetics and Non Food Products intended for Consumers (SCCNFP).
Administration of peptides is normally subcutaneous or intramuscular. Peptides come as a fine white and delicate powder that must be reconstituted with bacteriostatic water or medical grade saline. An insulin syringe should always be used to administer the dose. When targeting muscles, look for a place where the layer of skin and fat are lean. Mixing two peptides in the same syringe is totally fine but I personally would advise not drawing/mixing doses and storing pins for future use.
Django Nathan, a medical doctor with a degree in molecular biology and genetics, takes peptides because of his busy lifestyle: "Quite a few doctors I know are using them because they have so many beneficial effects and so few side effects. We're not elite athletes – we live rushed lives that can involve 70 hour weeks so staying fit and getting good sleep is essential – and peptides aid that."
In August 2010, the delegate confirmed the decisions of the June 2010 meeting of the NDPSC to transfer leflunomide to Appendix L. Appendix L was a new appendix created to list all of the requirements for dispensing labels previously included in the body of the Poisons Standard (i.e. paragraph 45, Dispensed Medicines, of Part 3, Miscellaneous Regulations) as part of the transitional amendments required to change the Standard for the Uniform Scheduling of Drugs and Poisons No. 24 into the Standard for the Uniform Scheduling of Medicines and Poisons No. 1, under the revised scheduling arrangements commencing 1 July 2010.
This particular peptide offers therapeutic benefits similar to those of hGH. CJC 1295 is a growth hormone releasing hormone (GHRH) analogue. In other words, it is a molecule that serves the same purpose as does GHRH—the hormone that stimulates the anterior pituitary to release hGH. However, unlike GHRH, which has a half-life of only minutes after IV administration, CJC 1295 is able to remain active in the body for extended periods due to its ability to bind to a protein in the blood known as albumin and avoid degradation by various enzymes. CJC 1295 increases an important growth factor, IGF-1, in addition to hGH, leading to fat loss, lean muscle growth, and enhanced sleep.
The DAC technology in the CJC-1295 enables the compound to bind itself covalently with any circulating albumin, after it has been administered through a subcutaneous injection. However, the reason why the half-life could be extended from a few minutes to several days is more profound. The reactive group in the CJC-1295 binds to a peptide through bioconjugation. The peptide then finds a neucleophilic unit within the blood and reacts with it in order to create a firmer bond.
The importance of limiting myocardial ischemia/reperfusion injury has been appreciated since Braunwald23,24 proposed that the extent and severity of tissue damage were not predetermined at the onset of ischemia, but could be modified by therapeutic manipulations applied during ischemia. Few years ago, a National Institutes of Health (NIH) expert’s panel concluded that cardioprotection is at a crossroads since approaches to identify cardioprotective therapies have been disappointing during the past 30 years.25 This may be related to the fact that the multiple candidates assayed so far target one single pathogenic event of the multiple damage cascade involved in myocardial damage and failure.25
×